Recursion Pharmaceuticals Q3 2024 Earnings Report

Recursion Pharmaceuticals EPS Results

• Actual EPS: -$0.34
• Consensus EPS: -$0.33
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: -$0.43

Recursion Pharmaceuticals Revenue Results

• Actual Revenue: $26.08 million
• Expected Revenue: $12.62 million
• Beat/Miss: Beat by +$13.46 million
• YoY Revenue Growth: +147.60%

Recursion Pharmaceuticals Announcement Details

• Quarter: Q3 2024
• Date: 11/6/2024
• Time: After Market Closes
• Conference Call Date: Wednesday, November 6, 2024
• Conference Call Time: 2:30AM ET

Recursion Pharmaceuticals (NASDAQ:RXRX) (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations. These data feed into proprietary machine-learning pipelines designed to uncover subtle phenotypic changes that traditional screening methods might miss. The company applies this approach to diverse therapeutic areas, including rare genetic diseases, oncology and immunology, with several preclinical programs in its pipeline. Partnerships with pharmaceutical firms and research institutions further extend Recursion’s reach and validate its platform in real-world drug discovery projects.

Founded in 2013 by Christopher Gibson and Blake Borgeson, Recursion Pharmaceuticals is headquartered in Salt Lake City, Utah, and maintains additional research facilities and corporate offices across North America and Europe. Following its initial public offering in early 2021, the company has continued to expand both its technological capabilities and its therapeutic focus. Led by CEO Christopher Gibson and a management team versed in biology, data science and automation engineering, Recursion is positioned to advance a new paradigm in drug discovery that bridges experimental data with predictive, AI-driven insights.